Theravance Biopharma, Inc.

NasdaqGM:TBPH Stock Report

Market Cap: US$447.5m

Theravance Biopharma Dividend

Dividend criteria checks 0/6

Theravance Biopharma hat in der Vergangenheit keine Dividende gezahlt.

Key information

n/a

Dividend yield

n/a

Payout ratio

Industry average yield2.3%
Next dividend pay daten/a
Ex dividend daten/a
Dividend per sharen/a
Earnings per share-US$1.15
Dividend yield forecast in 3Y0%

Recent dividend updates

No updates

Recent updates

Some Confidence Is Lacking In Theravance Biopharma, Inc.'s (NASDAQ:TBPH) P/S

Feb 05
Some Confidence Is Lacking In Theravance Biopharma, Inc.'s (NASDAQ:TBPH) P/S

Upgrade: Analysts Just Made A Sizeable Increase To Their Theravance Biopharma, Inc. (NASDAQ:TBPH) Forecasts

Nov 11
Upgrade: Analysts Just Made A Sizeable Increase To Their Theravance Biopharma, Inc. (NASDAQ:TBPH) Forecasts

Theravance to purchase $95M of ordinary shares

Sep 28

Things Look Grim For Theravance Biopharma, Inc. (NASDAQ:TBPH) After Today's Downgrade

Sep 21
Things Look Grim For Theravance Biopharma, Inc. (NASDAQ:TBPH) After Today's Downgrade

Theravance Biopharma announces $250M capital return program

Sep 19

Theravance Biopharma GAAP EPS of -$0.11, revenue of $11.1M

Aug 04

Theravance: All-Round Failure

Mar 10

Theravance Biopharma, Inc. (NASDAQ:TBPH) Analysts Just Trimmed Their Revenue Forecasts By 27%

Aug 09
Theravance Biopharma, Inc. (NASDAQ:TBPH) Analysts Just Trimmed Their Revenue Forecasts By 27%

Theravance Bio stock falls 6% after nezulcitinib flunks mid-stage COVID-19 induced lung injury study

Jun 21

Theravance Biopharma, Inc. (NASDAQ:TBPH) Analysts Are Reducing Their Forecasts For This Year

May 09
Theravance Biopharma, Inc. (NASDAQ:TBPH) Analysts Are Reducing Their Forecasts For This Year

Theravance Biopharma EPS misses by $0.16, misses on revenue

May 04

Shareholders May Not Be So Generous With Theravance Biopharma, Inc.'s (NASDAQ:TBPH) CEO Compensation And Here's Why

Apr 21
Shareholders May Not Be So Generous With Theravance Biopharma, Inc.'s (NASDAQ:TBPH) CEO Compensation And Here's Why

Don't Ignore The Fact That This Insider Just Sold Some Shares In Theravance Biopharma, Inc. (NASDAQ:TBPH)

Mar 13
Don't Ignore The Fact That This Insider Just Sold Some Shares In Theravance Biopharma, Inc. (NASDAQ:TBPH)

Is Theravance Biopharma, Inc. (NASDAQ:TBPH) Expensive For A Reason? A Look At Its Intrinsic Value

Mar 08
Is Theravance Biopharma, Inc. (NASDAQ:TBPH) Expensive For A Reason? A Look At Its Intrinsic Value

Stability and Growth of Payments

Fetching dividends data

Stabile Dividende: Es liegen keine ausreichenden Daten vor, um festzustellen, ob die Dividende je Aktie von TBPH in der Vergangenheit stabil geblieben ist.

Wachsende Dividende: Unzureichende Daten, um festzustellen, ob die Dividendenzahlungen von TBPH gestiegen sind.


Dividend Yield vs Market

Theravance Biopharma Dividend Yield vs Market
How does TBPH dividend yield compare to the market?
SegmentDividend Yield
Company (TBPH)n/a
Market Bottom 25% (US)1.5%
Market Top 25% (US)4.7%
Industry Average (Pharmaceuticals)2.3%
Analyst forecast in 3 Years (TBPH)0%

Bemerkenswerte Dividende: Es ist nicht möglich, die Dividendenrendite von TBPH im Vergleich zu den unteren 25 % der Dividendenzahler zu bewerten, da das Unternehmen keine aktuellen Ausschüttungen gemeldet hat.

Hohe Dividende: Es ist nicht möglich, die Dividendenrendite von TBPH im Vergleich zu den besten 25 % der Dividendenzahler zu bewerten, da das Unternehmen keine aktuellen Ausschüttungen gemeldet hat.


Earnings Payout to Shareholders

Abdeckung der Erträge: Unzureichende Daten zur Berechnung der Ausschüttungsquote von TBPH, um festzustellen, ob die Dividendenzahlungen durch die Gewinne gedeckt sind.


Cash Payout to Shareholders

Cashflow-Deckung: Es ist nicht möglich, die Nachhaltigkeit der Dividende zu berechnen, da TBPH keine Ausschüttungen gemeldet hat.


Discover strong dividend paying companies

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.